High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia
- 1 January 1992
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 6 (4-5) , 385-388
- https://doi.org/10.3109/10428199209053571
Abstract
Hairy cell leukemia (HCL) is almost constantly characterized by the presence of very high levels of a soluble form of the interleukin-2 receptor (sIL-2R). Since several other hematologic neoplasias also display very high levels of sIL-2R, this feature cannot be considered specific for HCL. On the other hand, most of the above hematologic disorders are also characterized by the presence of detectable levels of the soluble CD30 molecule (sCD30). In the present study we investigated the sera from 22 patients with HCL for the presence of detectable circulating levels of sCD30 in combination with the detection of sIL-2R. In this report we demonstrate that the high serum levels of sIL-2R found in all HCL patients were never associated with the presence of sCD30. Since this pattern is unlikely to be found in neoplastic conditions other than HCL, we suggest that the combined serum determinations of sIL-2R and sCD30 be used as a reliable additional tool for the diagnosis of HCL.Keywords
This publication has 13 references indexed in Scilit:
- Increased serum levels of soluble IL‐2 receptor, CD30 and CD8 molecules, and gamma‐interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanismsBritish Journal of Haematology, 1990
- Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stageBritish Journal of Haematology, 1990
- Serum levels of soluble interleukin-2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulkBritish Journal of Haematology, 1989
- Increased Levels of Soluble lnterleukin-2 Receptor in Non-Hodgkin’s Lymphomas: Relationship with Clinical, Histologic, and Phenotypic FeaturesAmerican Journal of Clinical Pathology, 1989
- Ki‐1 (CD30) antigen is released by Ki‐1‐positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki‐1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme‐linked immunosorbent assayEuropean Journal of Immunology, 1989
- THE SOLUBLE INTERLEUKIN‐2 RECEPTOR IN HAEMATOLOGICAL DISORDERSBritish Journal of Haematology, 1987
- The Human Interleukin-2 Receptor: Normal and Abnormal Expression in T Cells and in Leukemias Induced by the Human T-Lymphotropic RetrovirusesAnnals of Internal Medicine, 1986
- Immunohistological analysis of Tac antigen expression in tissues involved by Hodgkin's diseaseBritish Journal of Cancer, 1984
- Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.Journal of Clinical Investigation, 1984
- Rearrangement and expression of immunoglobulin genes and expression of Tac antigen in hairy cell leukemia.Proceedings of the National Academy of Sciences, 1983